The mechanism is due to changes in the immune microenvironment caused by WNT signaling inhibition and increased CD8+ T cell-mediated immune response, making pancreatic cancer sensitive to PD-L1 blockade therapy [212]. This evidence concerns the gene CD274 and pancreatic neoplasm.